Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia.
about
Heart Disease and Stroke Statistics--2013 Update: A Report From the American Heart AssociationCalsequestrin 2 and arrhythmiasAbsence of triadin, a protein of the calcium release complex, is responsible for cardiac arrhythmia with sudden death in humanDrug therapy in cardiac arrest: a review of the literatureNext-Generation Sequencing in Post-mortem Genetic Testing of Young Sudden Cardiac Death CasesCatecholaminergic polymorphic ventricular tachycardia: An exciting new eraRole of sodium and calcium dysregulation in tachyarrhythmias in sudden cardiac death.Molecular autopsy in victims of inherited arrhythmiasInherited ion channel diseases: a brief reviewRecent advances in genetic testing and counseling for inherited arrhythmiasCurrent topics in catecholaminergic polymorphic ventricular tachycardia2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of theCalsequestrin mutations and catecholaminergic polymorphic ventricular tachycardiaInherited dysfunction of sarcoplasmic reticulum Ca2+ handling and arrhythmogenesisExome Analyses of Long QT Syndrome Reveal Candidate Pathogenic Mutations in Calmodulin-Interacting GenesAntiarrhythmic Effects of Dantrolene in Patients with Catecholaminergic Polymorphic Ventricular Tachycardia and Replication of the Responses Using iPSC ModelsHeart disease and stroke statistics--2014 update: a report from the American Heart AssociationHeart disease and stroke statistics--2012 update: a report from the American Heart AssociationHeart Disease and Stroke Statistics-2017 Update: A Report From the American Heart AssociationPrevention of ventricular arrhythmia and calcium dysregulation in a catecholaminergic polymorphic ventricular tachycardia mouse model carrying calsequestrin-2 mutation.Risk stratification in electrical cardiomyopathies.Risk stratification in young patients with channelopathies.Therapeutic approach for patients with catecholaminergic polymorphic ventricular tachycardia: state of the art and future developments.Follow-up with exercise test of effort-induced ventricular arrhythmias linked to ryanodine receptor type 2 gene mutations.The role of stress test for predicting genetic mutations and future cardiac events in asymptomatic relatives of catecholaminergic polymorphic ventricular tachycardia probands.Catecholaminergic polymorphic ventricular tachycardia in a patient with recurrent exertional syncopeEffects of flecainide on exercise-induced ventricular arrhythmias and recurrences in genotype-negative patients with catecholaminergic polymorphic ventricular tachycardia.[Ion channel diseases in children].Sudden cardiac arrest during sex in patients with either catecholaminergic polymorphic ventricular tachycardia or long-QT syndrome: a rare but shocking experience.Catecholaminergic polymorphic ventricular tachycardia in children: analysis of therapeutic strategies and outcomes from an international multicenter registry.[Primary and secondary prophylactic ICD therapy in congenital electrical and structural cardiomyopathies].Catecholaminergic Polymorphic Ventricular Tachycardia with QT Prolongation.The Role of Flecainide in the Management of Catecholaminergic Polymorphic Ventricular Tachycardia.Utility of Post-Mortem Genetic Testing in Cases of Sudden Arrhythmic Death Syndrome.Optimizing catecholaminergic polymorphic ventricular tachycardia therapy in calsequestrin-mutant miceAlpha blockade potentiates CPVT therapy in calsequestrin-mutant mice.Impact of genetics on the clinical management of channelopathies.Inhibition of cardiac Ca2+ release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia.Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardiaPostpacing abnormal repolarization in catecholaminergic polymorphic ventricular tachycardia associated with a mutation in the cardiac ryanodine receptor gene.
P2860
Q22306356-3C24E8C4-118E-48F1-81BB-EF1CB6E9CA32Q24300626-FE6D35AF-4A9B-4C57-BE0A-7D97F9B60ECBQ24307681-61DAE3DF-C1CD-46EF-9F50-3D1A404466C1Q26741074-9A6CE842-5C89-4BFE-A25B-6092ABAC068DQ26745883-900FEC75-ED2F-46D6-808D-830E356C1C7DQ26747056-2580321A-9E8C-4F63-92A4-9ADE1CE5800DQ27339434-E8F561B8-75D7-4B2F-A641-7CE5BC6B86B0Q28069286-4EF4636A-778F-4DB6-9C3A-96A17AAFDCF7Q28071914-7C70EF0C-2F0F-4EAB-AD86-5E86056997CDQ28074154-89B5B96D-ED82-47B4-9ABC-4E95339D90CCQ28076784-657814CD-B3F6-4114-A3A4-87B02830972BQ28087002-B0881605-D194-45A6-BEE5-154C6D7FA8BDQ28262015-7CD5B320-82D1-4B05-BF7C-57A5C6025219Q28308142-A8183AFF-6ABD-470E-9A11-63339274F148Q28546038-69D5EB1E-AC53-4827-A94F-7405B4AA23B9Q28547114-C45AED69-7E76-4D97-9D73-E0DC73E5111AQ29547691-9BC1FB51-7071-4A84-B9B1-C74A3D076F58Q29547909-309A60EF-5A82-4A15-9D5F-6BC674C1A124Q30238784-0DC39E2B-ED2E-44C9-8D9A-DA75D160CF0BQ30498471-999A6E50-F17F-4697-8D15-FF95F4647101Q33158278-69749E96-84D9-494A-87B8-A0E5F6426EC8Q33158864-FF9086CB-8CC7-4715-9C9A-C106C75B2C59Q33160416-F850F33E-007F-4920-B5CA-F964C8A3C2BDQ33160839-6C6E9233-B370-49E0-AE18-74D59EFAB558Q33161041-49151F75-B118-4A9B-B33E-12F75825A481Q33161060-2F6518C6-CCEE-4FD5-9A10-8EDC1E6D320DQ33162208-FA78ACA8-F948-4919-BCCF-82C59E7495A5Q33164649-16160AB8-E882-4DA1-9D53-825281C78664Q33165068-3AC8AC67-42CB-4B06-9FE0-14F0C3F2AA42Q33165339-075B6D99-E472-441C-B2EF-63EAAF7B3F61Q33165762-F4269BA8-8AC4-4F9A-A6A5-412F8C004C16Q33166105-5B015AB7-D528-4EEC-BEC6-13F3B3DC831CQ33167418-BA20171A-8E90-4379-8482-C55B5FD2703DQ33603766-ED23E417-4BA1-412B-9CE3-FBA65CA98C5BQ33919047-B1FCF491-83B1-4812-87B4-4A176A74773FQ33940815-553EA762-0BEA-4EC6-B1A1-B436F1F55CD9Q34036797-93E0DEE9-50AA-45B3-AD10-BFD3B62A941CQ34160930-D03B4F04-E006-41E7-B137-C7C48B9526DEQ34629553-37B26BF3-23D0-4BDE-9C4C-E023878B1568Q35242390-8C48F5C3-0EB4-42C9-8F95-747B25AC2046
P2860
Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia.
description
2009 nî lūn-bûn
@nan
2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Incidence and risk factors of ...... rphic ventricular tachycardia.
@ast
Incidence and risk factors of ...... rphic ventricular tachycardia.
@en
type
label
Incidence and risk factors of ...... rphic ventricular tachycardia.
@ast
Incidence and risk factors of ...... rphic ventricular tachycardia.
@en
prefLabel
Incidence and risk factors of ...... rphic ventricular tachycardia.
@ast
Incidence and risk factors of ...... rphic ventricular tachycardia.
@en
P2093
P1433
P1476
Incidence and risk factors of ...... rphic ventricular tachycardia.
@en
P2093
Alice Maltret
Anne Messali
Antoine Leenhardt
Didier Klug
Elisabeth Villain
Isabelle Denjoy
Jean-Marc Lupoglazoff
Joël Kamblock
Joël Lunardi
Meiso Hayashi
P304
P356
10.1161/CIRCULATIONAHA.108.829267
P407
P577
2009-04-27T00:00:00Z